In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Bill Humphries, CEO at Alcami.
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Bill, covering:
The role managers, leaders, and mentors have played in shaping his illustrious career in dermatology
The importance of ‘force multiply’ in getting results and accelerating growth
Why, after a career spent on the drug sponsor side... he decided to switch to the CDMO services side
How do the shifting sands in the sector provide a treasure trove of opportunities?

Bill Humphries, Alcami CEO, is an experienced leader in the life sciences industry, previously serving as CEO at Isosceles Pharmaceuticals, President and Group Company Chairman of Ortho-Dermatologics, CEO of Merz North America, President of Stiefel, a GSK Company and Vice President of US Skincare at Allergan Pharmaceuticals. 
Bill also served as Chairman of the Board at Clearside Biomedical, Executive Chairman of Strata Skin Sciences, and a member of the Board of Directors at Aclaris Therapeutics, PhaseBio Pharmaceuticals, SKNV, and Bryn Pharmaceuticals. Humphries’ academic credentials include a B.A. from Bucknell University and an MBA from Pepperdine University.
Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!
Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital, and content agency that helps companies differentiate, get noticed, and grow in the life sciences.